pembrolizumab
Merck
['lenva', 'kcsm,(-skcsm)', 'rcc,(-irccs),(-srcc),(-urcc)', 'pembro']
first-line lenvatinib plus pembrolizumab elicits antitumor activity in non clear cell rcc #kcsm #esmo2022 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.